This site is for US residents only

GEOMETRYmono-1: Phase II Trial of INC280

Capmatinib (INC280)

A Phase II study for people with non-small cell lung cancer (NSCLC) that harbors a MET mutation and/or amplification

Call me back

For more information about Signature trials, enter your contact details and a representative will call you at your convenience.

*Required Information

*First Name
*Last Name
*Phone Number
*Zip Code
*Preferred time to call
*Time zone

Your email has been successfully sent

There was an error while sending your email

Call Now

1-855-405-5762

We are here to answer any questions you may have about participating in a Signature trial.

Trial Goal

To learn whether capmatinib (INC280) displays safe and effective antitumor activity in treating NSCLC in patients who have received 1 or 2 prior systemic therapies for their advanced cancer.

You may be eligible to participate if you

  • Have advanced NSCLC and have been treated for it
  • Have both confirmed EGFR wild-type and ALK-negative NSCLC
  • Have, as determined by a Novartis-approved laboratory, either c-MET amplification or c-MET mutation
  • Are 18 years of age or older
  • Meet other eligibility criteria

Depending on the type of tumor you have and/or prior treatments, you may not be eligible for this clinical trial. Please speak to your doctor. This clinical trial may close at any time.

Download the Doctor Discussion Guide